USP 795 그리고 797 펩타이드 문서화 가이드

무슨 USP 795 그리고 797 실제로 펩타이드 문서가 결정합니다

각 장에서는 준비를 분류합니다., 분자가 아니라. USP 795 그리고 797 펩타이드 문서화 질문은 하나의 방아쇠를 당깁니다.: 완성된 제제가 투여 시점에 멸균되어야 하는지 여부. 그 단 하나의 조건, 펩타이드의 순도나 가격 수준이 아닌, 귀하가 보유할 것으로 예상되는 기록을 관리하는 장을 결정합니다..

멸균 경로는 아래에 위치 <797>. 주사, IV 혼합물, 안과, 척수강 내 준비, 외부 환경과 소통하지 않는 체강에 대한 준비는 모두 그 선상에 있습니다.. 비멸균 제형, 경구액제 포함, 캡슐, 크림, 젤, 그리고 좌약, ~에 빠지다 <795> (NCPA, USP 배합 표준 <795> 그리고 <797> 프레젠테이션, 2026).

경계에는 개발자를 놀라게 하는 두 번째 장점이 있습니다.. 제조업체가 승인한 라벨링에 따라 엄격하게 제조된 기존 방식으로 제조된 멸균 제품은 범위 밖이라고 설명됩니다. <797>. 개별 환자에 대한 라벨링에 따라 기존 방식으로 제조된 비멸균 제품을 재구성하는 것, 나중에 사용하기 위해 저장하지 않고, 아래에 합성되지 않습니다 <795> (미시시피 약학위원회, <797> FAQ 문서, 2023).

구매를 잘못 분류하면 일상적인 품질 질문이 에스컬레이션으로 변합니다.. 주문 시점에 카테고리가 잘못되어 모든 다운스트림 문서 요청이 잘못된 표준에 따라 도착합니다..

연구급 공급, 개발 지원, 및 배합 관련 용도: 선 그리기

펩타이드가 속하는 카테고리는 사용 목적 및 라벨링에 따라 설정됩니다., 크로마토그램이 얼마나 깨끗해 보이는가가 아니라. 실험실 및 개발 작업을 지원하기 위해 연구 등급 펩타이드 공급망이 존재합니다.: 해당 자료에는 연구용으로만 라벨이 지정되어 있습니다., 그리고 그 라벨링은 그 상태를 확립하는 것입니다. HPLC 및 질량분석기를 통해 동일성과 순도를 보여주는 로트 분석 인증서로 물질 자체를 문서화합니다.. 그렇지 않다, 그 자체로, 해당 재료를 합성에 허용되도록 설정.

합성 경로에는 고유한 진입 조건이 있기 때문에 이러한 구별이 중요합니다., 그리고 두 프레임워크는 서로 다릅니다..

섹션 503A에 따라, 벌크 원료의약품은 해당 USP 또는 NF 모노그래프와 약국 조제에 관한 USP 장을 준수하는 경우에만 사용할 수 있습니다., 또는 모노그래프가 존재하지 않는 FDA 승인 의약품의 구성 요소입니다., 또는 503A 벌크 목록에 나타납니다. (FDA, 503A조에 따른 조제에 사용되는 벌크 원료의약품, 현재 콘텐츠 2026-05-14). 이것들은 대안이다, 순차적으로 만족해야 하는 체크리스트가 아닙니다.. 갈라져, 해당 물질은 유효한 분석 인증서와 함께 도착해야 하며 섹션에 따라 FDA에 등록된 시설에서 제조된 것이어야 합니다. 510 (FDA, 현재 콘텐츠 2026-05-14).

아웃소싱 시설은 더 좁은 규칙에 따라 운영됩니다.: 벌크 원료는 503B 벌크 목록에 있거나 조제 당시 FDA의 의약품 부족 목록에 있는 의약품을 조제하는 데 사용되는 경우에만 사용할 수 있습니다., 분포, 그리고 분배 (FDA, 배합에 사용되는 벌크 원료의약품, 현재 콘텐츠 2026-03-26).

반복되는 실수는 순도 수치를 카테고리 업그레이드로 취급하는 것입니다.. ≥98% HPLC 결과는 로트를 설명합니다., 규제 자세가 아니라.

문서 세트: 방어 가능한 기록에 실제로 포함되는 내용

방어 가능한 기록은 인증서 폴더가 아닙니다.. It is a set of artifacts where each one proves a specific obligation, and a reviewer can trace the chain from supplier lot to internal use lot without asking you a question.

그만큼 FDA guidance to compounders on knowing bulk suppliers frames the obligations directly: source API from FDA-registered facilities, hold valid certificates of analysis, and know what testing the supplier actually performs. Those three obligations map onto distinct records.

The chain-of-custody handoff is the artifact most often missing. Without it, a supplier lot number and an internal use lot number sit in separate systems with no recorded link, and a reviewer cannot confirm that the material in the vial is the material the COA describes.

Warning: The record that matters most is the one written when the numbers do not match. A discrepancy between in-house verification and the supplier COA, and the investigation that followed, is the document a quality reviewer will ask for first.

신원 테스트: 분자 확인, 미사뿐만 아니라

Identity testing is a separate control from purity, and a single intact-mass figure does not establish it. A mass that matches the expected molecular weight tells you something is present at that mass. It does not tell you the sequence is correct, that the counterion is what the label claims, or that the material is free of the non-peptide components that sit outside the peptide-related impurity thresholds.

서비스 그만큼 EMA guideline on development and manufacture of synthetic peptides draws that boundary explicitly. Impurities in synthetic peptides are grouped as peptide-related (잘림, 삭제, 산화, 탈아미드화, sequence variants) and non-peptide (반대이온, residual solvents and reagents such as TFA). Counterion identity and content, 잔여 TFA, and water content are separate control items, not part of the peptide-related impurity thresholds. A peptide identity testing package that reports only the peptide-related side leaves three control items unaddressed.

Method conditions are what make an identity result evaluable. 나는 Q2(R2) frames validation around specificity/selectivity, range, 정확성, and precision, with typical minimum experimental designs of 9 determinations across at least 3 concentration levels for accuracy and 9 determinations over 3 levels or 6 determinations at 100% of test concentration for precision. When assay and impurity share one test, the calibration range runs from the impurity reporting level up to 120% of the assay acceptance criterion.

So what does this mean for a supplier COA? An MS confirmation reported without method conditions cannot be evaluated. You cannot tell whether the method was specific to the sequence, what concentration levels were run, or whether the counterion was measured at all.

순도 평가: 백분율 뒤의 숫자 읽기

A purity percentage without method conditions, a chromatogram, and impurity context is not evaluable. “≥98%” from two suppliers can describe two different measurements, and peptide purity evaluation starts by asking what the number is measuring.

The threshold scale and the advertising scale are not the same scale. Under the Ph. 유로. general monograph “Substances for Pharmaceutical Use” referenced by the EMA guideline on the development and manufacture of synthetic peptides, peptide-related impurities are reported above 0.1%, identified above 0.5%, and qualified above 1.0%. Those are actions a manufacturer must take as impurity levels rise. A ≥98% HPLC figure is a headline result from one run, on one column, under one set of method conditions.

Typical reported COA practice for lyophilized synthetic peptides clusters around HPLC purity tiers of ≥95%, ≥98%, and ≥99%, intact-mass identity within about ±0.5 Da (or under 5 ppm on high-resolution instruments), water content roughly ≤5–8% by Karl Fischer, and retest or expiry windows of 12–24 months at −20 °C, 에 설명된 대로 supplier COA-reading guides. These are industry-typical values that vary by supplier. They are not acceptance criteria, and treating them as such is the pitfall: a single percentage read as a purity specification.

공급업체 자격: 증거 채점, 평판이 아님

Peptide supplier qualification is an evidence-scoring exercise, not a reputation check. The criteria are the same ones the earlier sections defined: 신원, 청정, method conditions, lot linkage, and change control. Score each supplier against those criteria and the choice becomes defensible on paper.

Three supplier-side errors recur. A COA arrives without method conditions, so the purity figure cannot be reproduced. A certificate of origin arrives without lot linkage, so the material cannot be traced to the site that made it. A change-notification clause is absent from the agreement, so a specification change reaches the buyer after the fact.

FDA’s guidance to compounders on knowing your bulk suppliers and its conditions for 503A bulk drug substances both point the same direction: the buyer carries the burden of establishing that the source is acceptable and reliable, a responsibility USP <795> assigns to the designated person. That is the standard to score against.

고급의: 사내 검증이 공급업체 COA와 일치하지 않는 경우

If you already run in-house verification, this is the record that decides whether the disagreement is a supplier problem or a method problem. The distinction matters because the two failures route to different owners, and treating a method problem as a supplier problem burns a relationship you may need later.

Re-check method conditions and system suitability before you re-test the lot. Column chemistry, mobile phase composition, 구배, and detector settings all shift results, and a system suitability failure invalidates the run regardless of what the sample contains. Only after your system passes should you re-inject the lot.

Then compare your method against the supplier’s stated method. The ICH Q2(R2) guideline frames validation around specificity, 정확성, 정도, and range, so if your method and the supplier’s differ on any of those characteristics, the two numbers are not measuring the same thing. Counterion identity and content, 잔여 TFA, and water content are separate control items, and a gap in any of them can explain a purity delta without either party being wrong.

Document the discrepancy with both data sets attached, then route the outcome through your designated person.

The caution is a prerequisite, not a comment on your competence: this sequence only resolves a disagreement if your own method carries documented validation and a defined acceptance criterion. Without those two things, you have two uncalibrated numbers and no basis for deciding which one to trust.

시작하기: 처음 세 가지 동작

The lowest-friction first action is not writing a new SOP. It is classifying every peptide lot you already hold, because the classification determines which documentation obligations apply at all. A lot that lands in the research-grade category carries a different evidence burden than one headed toward compounding-related use, and you cannot know which records are missing until each lot has a category.

단계 1: Classify the inventory. Run every existing lot through the classification table and mark its category. This is a desk exercise. It needs no supplier contact, no legal review, and no new template.

단계 2: Assemble what exists. For each lot in the compounding-related category, pull the certificate of analysis, the certificate of origin, and the lot linkage into one location, then mark what is absent. Missing items are findings, not failures. You are building the gap list that tells you where to spend effort.

단계 3: Score your suppliers. Take your top two or three suppliers through the qualification matrix, and open a change-notification conversation with any that score weakly. Suppliers who cannot answer a notification question in writing are telling you something useful before a quality question escalates.

The hesitation worth naming directly: this is not a compliance project that requires legal sign-off before it can begin. Classification and evidence-gathering are internal, reversible, and produce no external commitment. Start with the inventory, and let the gaps tell you what USP 795 그리고 797 peptide documentation work actually remains.

자주 묻는 질문

What does the difference between USP <795> 그리고 <797> mean for a peptide purchase?

It decides which documentation standard your record has to satisfy, not which supplier you buy from. USP <795> governs nonsterile compounded preparations and USP <797> governs sterile ones, so the same peptide can sit under either chapter depending on the physical form and handling route it is destined for. Buyers should confirm the intended use category first, because that choice determines the identity, 청정, and handling evidence the record must carry. 펩타이드 생산

COA가 98% 이상인 연구 등급 펩타이드를 복합 성분으로 사용할 수 있습니까??

아니요. A ≥98% purity figure describes the material’s assay result, not its suitability for a preparation, and research-grade supply is not manufactured or documented against compounding standards. The advertised percentage also says nothing about which impurities were detected, how they were identified, or whether they were qualified against a limit. Treat the research-grade label as a supply category, not as a compliance status.

유효한 분석 증명서에는 무엇이 포함되어야 합니까??

A defensible COA names the specific lot, the analytical method used for each test, the acceptance criterion, and the measured result, so a reviewer can trace the number back to the method that produced it. A document that reports a single purity percentage with no method conditions, no lot identifier, and no raw output is a summary, not evidence. The record should also state who performed the testing and when.

신원 테스트와 순도 테스트는 동일한 테스트입니까??

아니요. Identity testing confirms the molecule is what the label says it is; purity testing measures how much of everything else is present. A sample can pass an identity check and still fail on impurity profile, which is why the two belong in separate rows of the documentation set rather than collapsed into one line.

공급업체 인증을 얼마나 자주 반복해야 합니까??

Requalification should be triggered by change, not by the calendar alone. A new lot, a revised method, a relocated manufacturing site, or a change in the supplier’s own specification all warrant a fresh review of the evidence. A periodic re-check adds value mainly as a backstop for suppliers whose change notifications are unreliable.

RUO 라벨만으로 문제가 해결됩니까??

아니요. The research-use-only designation limits the claims a supplier can make about the material; it does not by itself establish or exclude anything about the buyer’s intended use. What settles the question is the documented chain from the material’s stated grade through to the use category the buyer has already identified.

불순물 보고는 어떻게 하나요?, 신분증, 자격 기준은 광고된 순도 등급과 다릅니다.?

They answer different questions. Reporting thresholds set the level at which an impurity must appear in the record at all; identification thresholds set the level at which its structure must be determined; qualification thresholds set the level at which it must be shown to be safe at the intended exposure. An advertised purity tier is a single headline number and carries none of that structure, which is why a high percentage and a clean impurity profile are not interchangeable claims.

결론

USP 795 그리고 797 peptide documentation is decided by the preparation and its intended use, not by the paperwork you assemble afterward: the category comes first, and every record you keep has to answer to it. That is the spine this guide has followed throughout. You draw the line between research-grade supply, development support, and compounding-related use. You build a record set that can survive a question. You confirm the molecule by identity testing rather than by mass alone, you read the purity percentage against the method that produced it, and you score supplier evidence on what it actually shows instead of on reputation. When in-house verification disagrees with a supplier COA, the disagreement itself is information, and it belongs in the file.

What moves is the enforcement posture, not the compendial requirements. Inspection attention, documentation expectations, and the questions buyers ask tend to shift faster than the standards they are built on, so a record set that is defensible today is the one that stays defensible when the scrutiny changes. Build for the requirement, not for the current mood.

This article is an educational overview. It is not legal, regulatory, or compliance advice, and it does not describe compounding services or compounded preparations. Consult qualified regulatory counsel or a licensed pharmacist for determinations about your own operations. MOL Changes operates in the peptide and life-sciences supply space, so treat this as a neutral commercial-interest disclosure rather than an independent assessment.

다음 단계

If you want to compare your current documentation set against the five-part framework above, request the analytical documentation package or speak with a technical specialist about the records that accompany your materials.